Hemas Pharmaceuticals (pvt) Ltd Pharmaceutical Import Profile — Sri Lanka (DGFT 2022–2026)

Name: Hemas Pharmaceuticals (pvt) Ltd Pharmaceutical Import Records from India — 4 Products, $2.1M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Hemas Pharmaceuticals (pvt) Ltd — Pharmaceutical Importer Profile (2026) | 4 Products, $2.1M Trade | TransData Nexus

Hemas Pharmaceuticals (pvt) Ltd

Pharmaceutical Importer · Sri Lanka · Nutritional Supplements Focus · $2.1M Total Trade · DGFT Verified

Hemas Pharmaceuticals (pvt) Ltd is a pharmaceutical importer based in Sri Lanka with a total trade value of $2.1M across 4 products in 4 therapeutic categories. Based on 59 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Hemas Pharmaceuticals (pvt) Ltd sources from 8 verified Indian suppliers, with Usv Private Limited accounting for 56.1% of imports.

Hemas Pharmaceuticals (pvt) Ltd — Import Portfolio & Supplier Network

Hemas Pharmaceuticals (pvt) Ltd import network — 4 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Hemas Pharmaceuticals (pvt) Ltd?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Usv Private Limited	$1.7M	104	56.1%
Zydus Lifesciences Limited	$580.6K	52	19.3%
Cadila Healthcare Limited

What Formulations Does Hemas Pharmaceuticals (pvt) Ltd Import?

Formulation	Value	Ships
Vageston 200MG CAPS progesterone	$100.0K	2
Kalzana tabs calcium with vitamins 10x10 under lut no.ad300323000664t dt.16.03.2023 valid up to	$89.6K	2
Ecorin-75 tablets 10's lk (10x10's)	$62.2K	2
Glycomet 500 sr tabs 10's lk (10x10's)	$50.0K	1
Kalzana tabs (calcium with vitamins)	$50.0K	1
Kalzana 500 tablets (calcium vitamin	$50.0K	1
Prednisolone acetate 5ML prednisolone	$50.0K	1
Glycinorm mr 30MG tablets gliclazide 47460 x 3 x 10's= 1423800	$50.0K	1
Jardiance ficta /90/10MG	$50.0K	1
Glycomet 500 sr tablets 5x2x20s lk (qty: 9581 car) batch-28025940-mfg dt.nov-2024-exp.	$50.0K	1
Glycomet 500 sr tablets 5x2x20s lk (qty: 9576 car)batch-28026063-mfg dt.dec-2024-exp.	$50.0K	1
Glycomet 500 sr tablets 5x2x20s lk (qty: 16438 car)batch-28026108 -mfg dt.dec-2024-exp. dt.nov-2026 & 28066118 mfg.	$50.0K	1
Glycomet 500 sr tablets 5x2x20s lk(qty:9576 car)batch no.28026297-mfg.dt.feb.2025	$50.0K	1
Glycomet 500 tablets 10s lk (2x5x10s)(qty: 63925 car)batch no.26010637 & 26010638-mfg.dt.feb.2025,exp.dt.jan.2028 &	$50.0K	1
Glycomet 500 tablets 10 s lk 2x5x10 s batch 26010695 26010696 26010699 26010700 26010701 26010702 26010703	$50.0K	1

Hemas Pharmaceuticals (pvt) Ltd imports 185 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 4 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Vitamin	Nutritional Supplements	$1.3M	25	0.9%	13
2	Methotrexate	Immunosuppressants	$435.1K	9	1.2%	19
3	Letrozole	Advanced Oncology	$277.4K	10	0.9%	11
4	Bisacodyl	Gastrointestinal	$122.6K	15	1.4%	10

Hemas Pharmaceuticals (pvt) Ltd imports 4 pharmaceutical products across 4 categories into Sri Lanka totaling $2.1M.

Hemas Pharmaceuticals (pvt) Ltd — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Hemas Pharmaceuticals (Pvt) Ltd, established in 1948, is a leading importer and distributor of pharmaceutical products in Sri Lanka. As a member of the Hemas Group, one of the country's most respected conglomerates, Hemas Pharmaceuticals has over seven decades of experience in shaping Sri Lanka's healthcare industry through innovation and an extensive distribution network.

The company offers a comprehensive portfolio, including pharmaceutical, surgical, diagnostics, consumer health, and animal health products. With a market share exceeding 30%, Hemas Pharmaceuticals serves over 3,000 pharmacies and 7,000 healthcare practitioners across the island, demonstrating its significant role in the nation's pharmaceutical distribution.

2Distribution Network

Hemas Pharmaceuticals operates a robust distribution network with a presence in over 3,000 pharmacies and 7,000 healthcare practitioners across Sri Lanka. This extensive reach is supported by a world-class supply chain system, ensuring steady product availability and efficient logistics. The company collaborates with more than 50 distributors, enhancing its capacity to deliver pharmaceutical products nationwide.

3Industry Role

As a primary wholesaler and distributor, Hemas Pharmaceuticals plays a pivotal role in Sri Lanka's pharmaceutical supply chain. The company imports and distributes a wide range of pharmaceutical products, surgical and diagnostic items, consumer health products, and animal health products. Its extensive distribution network and partnerships with over 50 multinational companies underscore its significant position in the market.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Hemas Pharmaceuticals (pvt) Ltd

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Hemas Pharmaceuticals imports finished pharmaceutical formulations from eight verified Indian suppliers, with USV Private Limited being the largest contributor, accounting for 56.1% of the total import value. This concentration indicates a strategic choice to maintain strong relationships with key suppliers, ensuring consistent product quality and availability. The company's diversified portfolio, with 185 unique formulations, suggests a balanced approach to sourcing, mitigating risks associated with single-source dependency.

2Supply Chain Resilience

Hemas Pharmaceuticals' supply chain demonstrates resilience through its diversified sourcing from multiple Indian suppliers, reducing reliance on any single source. The company's importation of 185 unique formulations indicates a broad product base, enhancing its ability to adapt to market changes. While specific details on backup suppliers and shipping routes are not publicly disclosed, Hemas' established partnerships and extensive distribution network suggest a well-structured and resilient supply chain.

3Strategic Implications

Importing Pharmaceuticals into Sri Lanka — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Sri Lanka

1Regulatory Authority & Framework

The National Medicines Regulatory Authority (NMRA) is the primary regulatory body overseeing pharmaceutical imports in Sri Lanka. Key legislation governing pharma imports includes the Medicines (Pricing Mechanism for Medicines) Regulations, which grant the NMRA authority to control medicine prices. Importers must register pharmaceutical products with the NMRA and obtain approval before distribution. As of February 2026, the NMRA has introduced new requirements for price submissions, particularly for import licenses expiring on or after 1st February 2026.

2Import Licensing & GMP

Importers must maintain active import licenses and renew them regularly. The NMRA requires that all pharmaceutical products imported into Sri Lanka be registered and approved before distribution. Importers are also required to submit import data in a specified format to the NMRA. Regarding Good Manufacturing Practice (GMP) certifications, the NMRA recognizes international standards such as EU GMP, WHO GMP, and PIC/S. Importers must ensure that their suppliers hold valid GMP certifications to comply with regulatory requirements. (nmra.gov.lk)

3Quality & Labeling

Hemas Pharmaceuticals (pvt) Ltd — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Hemas Pharmaceuticals focuses on importing products in therapeutic areas such as nutritional supplements, immunosuppressants, and advanced oncology. The significant import value in these categories indicates a strategic alignment with market demand and the company's expertise. The emphasis on nutritional supplements (59.9%) and immunosuppressants (20.9%) suggests a commitment to addressing prevalent health concerns in Sri Lanka.

2Sourcing Profile

Hemas Pharmaceuticals' sourcing strategy emphasizes importing finished pharmaceutical formulations from reputable suppliers, primarily from India. The company's diversified product portfolio, with 185 unique formulations, reflects a comprehensive approach to meeting the diverse healthcare needs of the Sri Lankan market.

3Market Positioning

Hemas Pharmaceuticals serves a broad segment of the Sri Lankan market, including retail pharmacies, hospitals, government tenders, and wholesale distribution. Its extensive distribution network and diverse product portfolio enable the company to cater to various healthcare providers and consumers across the country.

Seller's Guide — How to Become a Supplier to Hemas Pharmaceuticals (pvt) Ltd

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Hemas Pharmaceuticals, particularly in therapeutic areas where the company has a significant market presence. Identifying gaps in Hemas' current sourcing, such as emerging therapeutic categories or innovative formulations, could present avenues for new partnerships.

2Requirements & Qualifications

Indian exporters seeking to supply Hemas Pharmaceuticals must ensure their products are registered with the NMRA and comply with Sri Lankan import regulations. Suppliers must hold valid GMP certifications recognized by the NMRA, such as EU GMP, WHO GMP, or PIC/S. Adherence to quality standards, including batch testing, stability requirements, and labeling mandates, is essential.

3How to Approach

Indian exporters should initiate contact with Hemas Pharmaceuticals by presenting their product portfolios and demonstrating compliance with NMRA regulations. Participating in tenders and engaging in discussions about regulatory filing strategies can facilitate collaboration. Understanding the regulatory framework and aligning with Hemas' product strategy will enhance the potential for a successful partnership.

Frequently Asked Questions — Hemas Pharmaceuticals (pvt) Ltd

What products does Hemas Pharmaceuticals (pvt) Ltd import from India?

Hemas Pharmaceuticals (pvt) Ltd imports 4 pharmaceutical products across 4 categories. Top imports: Vitamin ($1.3M), Methotrexate ($435.1K), Letrozole ($277.4K), Bisacodyl ($122.6K).

Who supplies pharmaceuticals to Hemas Pharmaceuticals (pvt) Ltd from India?

Hemas Pharmaceuticals (pvt) Ltd sources from 8 verified Indian suppliers. The primary supplier is Usv Private Limited (56.1% of imports, $1.7M).

What is Hemas Pharmaceuticals (pvt) Ltd's total pharmaceutical import value?

Hemas Pharmaceuticals (pvt) Ltd's total pharmaceutical import value from India is $2.1M, based on 59 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Hemas Pharmaceuticals (pvt) Ltd focus on?

Hemas Pharmaceuticals (pvt) Ltd imports across 4 categories. The largest: Nutritional Supplements (59.9%), Immunosuppressants (20.9%), Advanced Oncology (13.3%).

Get Full Hemas Pharmaceuticals (pvt) Ltd Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.